AEON CO

Aeon is positioning itself in the growing longevity market with costly preventive checks, including blood tests and MRIs, to identify previously undetected risks early. Industry representatives such as KBL see opportunities for devices, supplements and combined offerings, but warn against buzzword use and unclear scientific evidence. Researchers emphasize that proven measures like exercise and not smoking still have the strongest evidence for a longer healthy lifespan, while definitive studies on many longevity interventions are still missing. » More on faz.net

Aeon Co. reports record profits for Q4 2025: EPS was 30.94 versus expected 29.88, while revenue of ¥2.97 trillion was slightly below forecasts of ¥2.99 trillion. Operating profit rose 13.8% to ¥270.4 billion, and profit attributable to owners climbed 167.5% to ¥72.6 billion. The stock fell about 10% to ¥1,763 after the announcement. Management plans to expand the private brand Topvalu, invest in digital transformation and supply-chain optimization; target for 2026 is a 16.7% revenue increase, with elevated personnel and energy costs remaining as risks. » More on de.investing.com

AEON will publish its quarterly results for the period ended Feb. 28, 2026, on April 9, 2026. One analyst forecasts EPS of $0.213 versus $0.110 a year earlier, and four analysts expect quarterly revenue averaging $19.05 billion (+10.07% year‑over‑year). For the past fiscal year, expected average EPS is $0.155 and revenue $68.14 billion. » More on finanzen.net